Cagrilintide (AM833)

Evidence Anchor

BioHarmony 5.8/10

Cagrilintide lands at a neutral score because it is a legitimate, Phase 3-validated drug whose best use is not the one this report scores. As monotherapy it delivers real weight loss of about 11.8 percent with a cleaner tolerability profile than the GLP-1 drugs, per Garvey 2025, but it underperforms semaglutide alone and is far below the CagriSema combination it was built for. It is unapproved, grey-market only, has no cardiovascular outcome trial, and regains weight on the class norm when stopped. For most people chasing weight loss, an approved GLP-1 drug is the better standalone choice. Cagrilintide is most interesting as the amylin half of a combination, and as a research subject, not as a solo intervention you would reach for first. The honest framing is that this is a real drug stuck in an awkward window: validated enough to take seriously, not approved enough to get cleanly, and outclassed enough as a solo act that the people most excited about it are usually the ones who misunderstand what it is. If that changes with approval, the verdict here moves up fast. ✅ Best for: Researchers and informed self-experimenters who specifically want the amylin pathway rather than a second GLP-1 drug, and who understand cagrilintide's real role is inside CagriSema. People who cannot tolerate GLP-1 nausea and want the lower-nausea, no-hypoglycemia profile of an amylin analogue. Those who want a separate, additive mechanism to stack with semaglutide and accept they are reproducing the CagriSema combination off-label. Anyone who can source pharmaceutical-grade material with a verified certificate of analysis and will rotate injection sites. People who treat this as an investigational tool with monitoring, not a proven product. ❌ Avoid if: You are pregnant or breastfeeding, since there is no human safety data for those groups. You have a history of pancreatitis or severe gastrointestinal disease, because slowed gastric emptying can worsen symptoms. You want the strongest standalone weight loss, in which case semaglutide, tirzepatide, or the combination are better supported. You need cardiovascular safety reassurance, since no outcome trial exists. You cannot verify product quality, because grey-market contamination and mislabeling can exceed the drug's own modest risk. You expect a permanent fix, given the class-norm rebound once dosing stops.

Read the full BioHarmony report

My score and my verdict: one signal of three, never the whole answer.